How Does Patent Prosecution Litigation Differ in New York Courts?

Administrative Patent Judges at the Patent Trial and Appeal Board apply a preponderance of the evidence standard, meaning the challenger must prove invalidity is more likely than not. However, once a party raises a prima facie case of unpatentability, the burden shifts to the patent owner to rebut that showing with evidence. This burden-shifting framework differs from district court litigation, where the plaintiff (typically the patent owner) bears the burden of proving infringement and validity throughout. Early documentation of inventorship, priority dates, and technical differences from prior art becomes essential at the administrative stage because the record created there will be reviewed by courts if litigation follows.

When a patent application survives examination and issues, the prosecution history becomes part of the patent record. U.S. District Courts in New York, including the Southern District and Eastern District of New York, apply the doctrine of prosecution history estoppel, which can narrow the scope of patent claims based on arguments or amendments made during prosecution. If a patent holder or patent owner narrowed a claim to overcome an examiner rejection, that narrowing may later prevent the owner from asserting a broader interpretation against an accused infringer. This doctrine operates as a significant procedural constraint that patent holders must evaluate before filing suit, because the prosecution history is public and creates evidentiary admissions that courts treat as binding.

A central procedural event in federal patent litigation is the Markman hearing, named after a seminal case, where the court construes the meaning of patent claim terms before trial. In New York federal courts, the judge (not a jury) determines what the patent claims mean, and this construction often determines the outcome of the case. The claim construction process requires detailed briefing on the patent specification, prosecution history, and expert testimony regarding how those terms would be understood by a person skilled in the relevant art. Patent holders should understand that an unfavorable claim construction can render a patent narrower than anticipated and may eliminate infringement liability if the accused product falls outside the narrowed claim scope.

Defendants in federal patent litigation routinely assert that a patent is invalid under 35 U.S.C. § 101 (subject matter eligibility), § 102 (novelty), § 103 (non-obviousness), or § 112 (written description and enablement). Federal courts in New York apply the same substantive standards as other circuits, but procedural timing differs. A defendant may raise validity challenges in a motion to dismiss, a summary judgment motion, or at trial, and the burden of proving invalidity rests with the defendant (by clear and convincing evidence at trial). However, if the defendant files an inter partes review petition at the Patent and Trademark Office during litigation, the administrative proceeding may run parallel to the district court case, creating strategic complexity and potential for inconsistent outcomes.

When inter partes review and district court litigation proceed in parallel, the administrative proceeding often moves faster than district court discovery and trial. If the Patent Trial and Appeal Board issues a final written decision invalidating claims, that decision may be cited in the district court case, and the district court may stay or dismiss the infringement claims. Conversely, if the Board upholds the patent, the defendant may appeal to the Federal Circuit while the district court case continues. Patent holders must coordinate litigation strategy and avoid making admissions in one forum that undermine their position in another. Practical risk management includes documenting technical positions consistently and ensuring that expert reports and declarations align across proceedings.

In addition to damages, a prevailing patent owner may seek an injunction prohibiting the defendant from further infringement. The test for preliminary injunction in patent cases requires showing likelihood of success on the merits, irreparable harm, balance of equities, and public interest. Since the Supreme Court's decision in eBay Inc. .. MercantileExchange.com, courts no longer presume that infringement warrants an injunction, and patent holders must prove that monetary damages are inadequate. New York federal courts apply this framework, and preliminary injunctions in patent cases are relatively rare. However, the threat of an injunction often provides settlement leverage, and patent holders should evaluate this remedy early in case planning.

Early in a patent dispute, patent holders should preserve all documents related to invention, development, testing, and commercialization. If a dispute escalates to litigation, failure to preserve relevant documents can result in sanctions, adverse inference instructions, or case dismissal. In practice, these disputes rarely map neatly onto a single rule, and courts may weigh competing factors differently depending on the record and the parties' conduct. Patent holders should consult with counsel before discarding technical files, communications with inventors, or sales records, because these materials often become critical evidence in both administrative and judicial proceedings. Establishing a litigation hold and documenting the scope of preservation efforts protects against later claims of spoliation and demonstrates good faith compliance with discovery obligations.

As a patent holder or patent owner evaluating a potential prosecution or infringement dispute, consider documenting the technical basis for your invention, maintaining detailed records of prior art searches and patent prosecution decisions, and understanding which forum (administrative or federal court) is most appropriate for your claim. Early consultation with counsel regarding claim scope, validity risks, and available remedies can clarify litigation costs and timeline expectations. If you are facing a competitor's challenge to your patent or if you suspect infringement, gathering evidence of harm, documenting your product features and the accused competitor's design, and preserving communications with inventors and business partners will strengthen your position regardless of which forum ultimately resolves the dispute. Additionally, review your patent portfolio for potential issues related to New York broker fee caps if your business involves licensing or technology transfer agreements, and consider consulting on compliance with New York public health law if your patent relates to medical devices or pharmaceutical applications.